Minerva Neurosciences (NASDAQ:NERV) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research note published on Friday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a “neutral” rating and set a $5.00 target price on shares of Minerva Neurosciences in a report on Wednesday, November 6th.

Minerva Neurosciences Stock Up 0.9 %

Shares of Minerva Neurosciences stock opened at $2.16 on Friday. The stock has a market cap of $15.10 million, a P/E ratio of -4.91 and a beta of 0.11. Minerva Neurosciences has a 12-month low of $2.06 and a 12-month high of $13.49. The business’s 50 day moving average is $2.32 and its 200-day moving average is $2.73.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.